trié(s) par (Pertinence décroissant(e), Titre croissant(e)) 

Article

Fractionated Stereotactic Radiation Therapy for Pituitary Adenomas: An alternative escalating protocol of hypofractionated stereotactic radiotherapy delivering 35Gy in 5 fractions

S. Sumodhee ; V. Atallah ; R. Kinj ; J. Doyen ; B. L’Homel ; P. Gillon ; P. Paquis ; F. Almairac ; S. Hieronimus ; R. Schiappa ; J.-L. Sadoul ; D. Sumodhee ; N. Pontikos ; Q. Richier ; Jean-Michel Hannoun-Lévi ; C. Scouarnec ; N. Chevalier ; P.-Y. Bondiau |

Dans Cancer/Radiothérapie (vol. 26, no. 4, Juin 2022)

Purpose Evaluate efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) for patients treated for pituitary adenoma (PA) with an alternative HSRT escalating protocol delivering 35Gy in 5 fractions. Material and methods From Ju[...]

Plus d'information... En ligne

Article

Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer

S. Sumodhee ; L. Guo ; L. Bouhlel ; A. Picard ; J. Otto ; A.O. Naghavi ; Q. Richier ; A. Levy ; P.-Y. Bondiau ; M. Poudenx ; T. Passeron ; Jean-Philippe Lacour ; H. Montaudié ; J. Doyen |

Dans Cancer/Radiothérapie (vol. 26, no. 8, Novembre 2022)

Purpose Preclinical and clinical data suggest a potential benefit in the addition of radiotherapy (RT) to immune-checkpoint inhibitors (ICI) during the treatment of advanced cancers. Nevertheless, the ideal patients for this approach and the opt[...]

Plus d'information... En ligne